By B.A. Utterback, Founder, PepScribe
My family lives in medicine every day. Around one table you will find the people who deliver care, doctors and clinicians who spend their lives treating patients, and the people who deal with what happens when care goes wrong, including medical malpractice attorneys. Growing up with both gave me a holistic view of compliance and care: I heard how a good clinical decision gets made, and I also heard, in detail, how bad ones end up in depositions.
That view shaped how I built PepScribe, a telehealth practice for peptide and hormone therapy, more than any market analysis did. Telehealth is a young industry with an old temptation: the faster you remove friction, the faster you grow, and most of what people call friction in health care is somebody’s safeguard. The doctors in my family taught me which safeguards protect patients. The attorneys taught me which removed safeguards show up later as exhibits.
So the company runs on two rules that never flex. A licensed clinician reviews every case and decides whether to prescribe. And every dose is compounded in the USA by licensed 503A pharmacies, the pharmacy class that prepares medication for an individual patient’s prescription. No hidden overseas supply chain. Everything else about the product is negotiable; those two are structural.
Testosterone is the clearest example of what that means in practice. It is a Schedule III controlled medication, and our testosterone program is built the way the classification demands: a live video visit with a licensed clinician, government ID verification, and recent labs before any prescribing decision. The clinician decides from the bloodwork, and a common, correct outcome is that the patient’s levels are normal and testosterone is not the answer. A program designed only for growth would treat that outcome as churn. A program designed around the clinical decision treats it as the product working.
The billing model follows the same logic. The online visit at PepScribe is free: a payment method is saved with a zero-dollar authorization, and money moves only if a clinician prescribes. I did not invent that structure to be generous. I built it because a consult fee makes the patient pay to hear no, and a platform that profits from every visit regardless of outcome has quietly put its incentives on the wrong side of the exam. When declining a patient costs the company money, the company has a reason to keep its screening honest. My attorney relatives would call that aligning incentives before discovery does it for you.
Compliance in this category also means being plain about what the products are. Compounded medications are prepared for an individual patient under a prescription, and they are not FDA-approved drugs. That sentence appears on our surfaces because it is true, and because the alternative, letting a buyer assume otherwise, is the kind of ambiguity that feels harmless in a marketing meeting and very different when read aloud later. The same goes for pricing: our plans publish the full monthly figure, medication, clinician care, and shipping in one number, before anyone commits.
I will not pretend this posture is free. Requiring labs loses the customer who wants a vial tonight. Free visits mean absorbing the cost of every no. US-only 503A compounding costs more than the alternatives that exist offshore. Every one of those costs has a competitor somewhere happily not paying it, and some of them are growing quickly. But my family’s dinner-table education points one direction here: in health care, the companies that treat safeguards as friction are borrowing against a bill that always arrives.
Telehealth deserves better than its shortcuts, because the underlying change is genuinely good. A man who has not seen a doctor in five years will complete an intake at midnight. A patient three hours from the nearest specialist can get a real clinical review this week. Those are wins for care, and they only stay wins if what is on the other end of the form is actual medicine: a licensed human deciding, a regulated pharmacy compounding, a price the patient saw first.
Care and compliance are usually discussed as a tradeoff. Growing up where I did, I learned they are the same discipline practiced at different distances from the patient.
Compounded medications are prepared for individual patients by licensed 503A pharmacies and are not FDA-approved drugs. All prescribing decisions at PepScribe are made by licensed clinicians.
AUTHOR BOX:
B.A. Utterback is the founder of PepScribe, a telehealth practice for peptide and hormone therapy. He is a former Emergency Medical Technician who went on to an executive career in technology, including creating medical mobile applications.